NDMA & NDEA: What’s the Difference?

In July 2018, the FDA recalled certain batches of valsartan after investigators found N-Nitrosimethylamine (NDMA) had contaminated the drug. Since then, several batches of valsartan, irbesartan, and losartan have been recalled due to NDMA and N-Nitrosodiethylamine (NDEA) contamination. These nitrosamines are classified as probable human carcinogens.

How Are They Similar?

NDMA and NDEA are both classified by the Environmental Protection Agency as probable human carcinogens. Exposure to these carcinogens can cause tumors to develop in the respiratory tract. Specifically, an individual may develop liver, stomach, colorectal, pancreatic, prostate, esophageal, and/or intestinal cancer. Exposure has also been linked to non-hodgkin’s lymphoma, leukemia, and multiple myeloma.

What’s the Difference?

The main difference between NDMA and NDEA is toxicity. NDEA happens to be about three times more toxic than NDMA.

What Should I Do?

If you or a loved one took a recalled valsartan, irbesartan, or losartan and developed prostate cancer (before age 60), lower esophageal cancer, non-hodgkins lymphoma, leukemia, multiple myeloma, colon, stomach, intestinal, or pancreatic cancer, please fill out the form below. We deliver the Gold standard advocacy you deserve.

New Carcinogen Found in Losartan

On February 28, 2019, the FDA recalled 87 lots of losartan after finding trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA). NMBA is the third nitrosamine found in the angiotensin II receptor blocker (ARB) medicines valsartan, losartan, and irbesartan.  NDMA and NDEA, two other nitrosamines, were previously found in these drugs leading to numerous recalls.

Like NDMA and NDEA, NMBA is considered a probable human carcinogen. The FDA has concluded that the levels of NMBA found in the recalled lots are higher than the FDA’s interim acceptable intake limits. The nitrosamines found in the ARB medications can cause numerous types of cancer including liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, and multiple myeloma.

The most recent recall includes lots from Camber Pharmaceuticals, Inc. The full list of recalled products can be found on the FDA’s website. If you or a loved one took a recalled product, contact your doctor before you stop taking the product.

GoldenbergLaw is currently accepting valsartan, irbesartan, and losartan cases in which an individual was diagnosed with liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma. Contact us for a free case consultation.

Valsartan Recall Expands: Mylan Recalls Over 100 Lots

Pharmaceutical company Mylan is recalling some of its blood pressure medications due to cancer concerns. The medications recalled all contain Valsartan. Since July 2018, the FDA has been recalling Valsartan due to finding trace amounts of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), which are classified as probable human carcinogens by the Environmental Protection Agency.

Mylan has recalled a total of 119 lots of medication containing Valsartan, including Amlodipine and Valsartan Tablets, Valsartan Tablets, and Hydrochlorothiazide Tablets. The list of all recalled lots can be found here.

This is the largest recall in FDA history. Mylan joins a growing number of companies that have recalled lots that contain Valsartan, Irbesartan, and Losartan due to carcinogen contamination. GoldenbergLaw is committed to holding these pharmaceutical companies accountable. If you or a loved one has taken Valsartan, Irbesartan, or Losartan and have been diagnosed with cancer, contact GoldenbergLaw.